Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit
Transgenic Research · 2021-08 · 30 (4) · 585-599
DOI: 10.1007/s11248-021-00237-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Transgenic Research, online erschienen am 15.03.2021. Verfasst von Osmat Azzam Jefferson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cambia, GPO Box 3200, Canberra, ACT, 2601, Australia. osmat.jefferson@cambia.org. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Genome, Plant, Private Sector. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, Alfred P. Sloan Foundation.
Abstract (Originalsprache)
CRISPR-Cas9 is a revolutionary technology because it is precise, fast and easy to implement, cheap and components are readily accessible. This versatility means that the technology can deliver a timely end product and can be used by many stakeholders. In plant cells, the technology can be applied to knockout genes by using CRISPR–Cas nucleases that can alter coding gene regions or regulatory elements, alter precisely a genome by base editing to delete or regulate gene expression, edit precisely a genome by homology-directed repair mechanism (cellular DNA), or regulate transcriptional machinery by using dead Cas proteins to recruit regulators to the promoter region of a gene. All these applications can be for: 1) Research use (Non commercial), 2) Uses related product components for the technology itself (reagents, equipment, toolkits, vectors etc), and 3) Uses related to the development and sale of derived end products based on this technology. In this contribution, we present a prototype report that can engage the community in open, inclusive and collaborative innovation mapping. Using the open data at the Lens.org platform and other relevant sources, we tracked, analyzed, organized, and assembled contextual and bridged patent and scholarly knowledge about CRISPR-Cas9 and with the assistance of a new Lens institutional capability, The Lens Report Builder, currently in beta release, mapped the public and commercial innovation pathways of the technology. When scaled, this capability will also enable coordinated editing and curation by credentialed experts to inform policy makers, businesses and private or public investment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cambia, GPO Box 3200, Canberra, ACT, 2601, Australia. osmat.jefferson@cambia.org.
- Queensland University of Technology, Brisbane, Australia. osmat.jefferson@cambia.org.
- Cambia, GPO Box 3200, Canberra, ACT, 2601, Australia.
ORCID-Profile: Osmat Azzam Jefferson, Simon Lang, Kenny Williams, Deniz Koellhofer, Aaron Ballagh, Ben Warren, Roshan Sharma, Richard Jefferson
Förderung
- Bill and Melinda Gates Foundation
- Alfred P. Sloan Foundation
Zitieren
APA
Jefferson, O. A., Lang, S., Williams, K., Koellhofer, D., Ballagh, A., Warren, B., Schellberg, B., Sharma, R., & Jefferson, R. (2021). Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit. Transgenic Research, 30(4), 585-599. https://doi.org/10.1007/s11248-021-00237-y
Vancouver
Jefferson OA, Lang S, Williams K, Koellhofer D, Ballagh A, Warren B, et al. Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit. Transgenic Research. 2021;30(4):585-599. doi:10.1007/s11248-021-00237-y
BibTeX
@article{Jefferson2021,
author = {Jefferson, Osmat Azzam and Lang, Simon and Williams, Kenny and Koellhofer, Deniz and Ballagh, Aaron and Warren, Ben and Schellberg, Bernard and Sharma, Roshan and Jefferson, Richard},
title = {Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit},
journal = {Transgenic Research},
year = {2021},
volume = {30},
number = {4},
pages = {585--599},
doi = {10.1007/s11248-021-00237-y}
}
EUVIMED